Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.7× sales vs its 0.5× historical median P/S.
Fair value ≈ $10.48 · price $13.80 today
Overvalued · 32% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$EHAB Excellent article that nails exactly where EHAB stands right now. So if you want to update your EHAB knowledge or get acquainted with EHAB, this is a must read. https://everyticker.com/quote/EHAB/analysis/enhabit-s-private-equity-premium-why-kinderhook-paid-24-more-for-a-turnaround-story-nyse-ehab
$EHAB Q1 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.37 up 5.71% YoY
• Reported revenue of $264.8M up 1.89% YoY
• Enhabit Inc expects a 2.4% estimated net increase to hospice payments for fiscal year 2027, effective October 1, 2026, and anticipates spending approximately $5M for maintenance capital expenditures during 2026.
$EHAB: Enhabit Inc. sets stockholder meeting date of May 12, 2026, to approve transaction with Kinderhook; expected to close in the second quarter of 2026 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260417062751EHAB&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
$EHAB Q4 '25 Earnings Results & Recap
Enhabit reported total net service revenue of $270.4M and consolidated Adjusted EBITDA grew 11.6% year over year to $28M, with Adjusted diluted EPS of $0.14.
$EHAB healthcare services Behavioral health operator tied to reimbursement rates and occupancy levels. Earnings and guidance revisions drive re rate. Any state level contract win is material. Does margin inflect this year?
